ARTICLE | Company News
Pharmacyclics, Alcon Laboratories Inc. deal
October 22, 2001 7:00 AM UTC
PCYC regained from Alcon global rights to develop and market Optrin motexafin lutetium to treat age-related macular degeneration (AMD) and other retinal diseases. In 1997, Alcon signed an evaluation a...